Şunu aradınız:: tpo (Slovence - İngilizce)

aminokislinsko zaporedje romiplostima ni homologno endogenemu tpo.
romiplostim has no amino acid sequence homology to endogenous tpo.

vendar ta protitelesa niso navzkrižno reagirala z endogenim tpo.
of the 271 adult itp patients receiving romiplostim in the itp clinical programme one patient developed antibodies capable of neutralising the activity of romiplostim but these antibodies did not cross react with endogenous tpo.

receptorji tpo so izraženi predvsem na površini celic mieloične vrste.
the tpo receptor is predominantly expressed on the surface of cells of the myeloid lineage.

odstranjevanje romiplostima v serumu je deloma odvisno od receptorjev tpo na trombocitih.
the elimination of serum romiplostim is in part dependent on the tpo receptor on platelets.

stimulatorji receptorjev tpo bi teoretično lahko spodbudili napredovanje obstoječih hematopoetskih malignomov ali mds.
for tpo receptor stimulators there is a theoretical concern that they may stimulate the progression of existing haematopoietic malignancies or mds.

v predkliničnih in kliničnih preskušanjih nobeno protitelo proti romiplostimu ni navzkrižno reagiralo z endogenim tpo.
in pre-clinical and clinical trials no anti-romiplostim antibodies cross reacted with endogenous tpo.

zaradi unikatne specifičnosti tpo receptorjev eltrombopag ne stimulira produkcije trombocitov pri miših, podganah ali psih.
eltrombopag does not stimulate platelet production in mice, rats or dogs because of unique tpo receptor specificity.

stimulatorji receptorjev tpo so rastni faktorji, ki povzročijo ekspanzijo in diferenciacijo trombopoetskih matičnih celic ter nastajanje trombocitov.
tpo receptor stimulators are growth factors that lead to thrombopoietic progenitor cell expansion, differentiation, and platelet production.

incidenca že obstoječih protiteles proti romiplostimu je bila 8,0% in proti tpo 5,4%.
the incidence of pre- existing antibodies to romiplostim and tpo was 8.0% and 5.4%, respectively.

vsaka enoverižna podenota je na c- terminalnem delu kovalentno vezana na peptidno verigo, ki ima 2 vezavna odseka za tpo.
the peptibody molecule is comprised of a human immunoglobulin igg1 fc domain, with each single-chain subunit covalently linked at the c-terminus to a peptide chain containing 2 tpo receptor-binding domains.

farmakokinetika romiplostima vključuje tarčno posredovano odstranjevanje, ki domnevno poteka preko receptorjev tpo na trombocitih in drugih celicah trombopoetske vrste, npr. na megakariocitih.
the pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by tpo receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes.

agonisti trombopoetinskih receptorjev (tpo-r) so rastni faktorji, ki povzročijo ekspanzijo trombocitopoetičnih matičnih celic, diferenciacijo in tvorbo trombocitov.
tpo-r agonists are growth factors that lead to thrombopoietic progenitor cell expansion, differentiation and platelet production.